All In Biotech

Drug Trial Radar · NCT06214156

A Clinical Study of T3011 in Subjects With Advanced Melanoma

A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 26, 2024

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

Conditions

  • Advanced Melanoma

Interventions

  • T3011Biological

    T3011 will be given intratumorally, Q2W;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Approximately 2 years
  2. Objective response rate(ORR)Time frame: Approximately 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Chengdu Shangjin Nanfu Hospital

    Chengdu, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • The Third People's Hospital of Zhengzhou

    Zhengzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Zhongshan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.